Enzene Biosciences Ltd.
Clinical trials sponsored by Enzene Biosciences Ltd., explained in plain language.
Biotech developing biosimilars and novel biologics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New osteoporosis drug shows promise in Head-to-Head trial
Disease control CompletedThis phase 3 trial tested a new biosimilar drug called ENZ215 (a form of denosumab) against the established drug Prolia in 504 postmenopausal women with osteoporosis. The goal was to see if ENZ215 works as well as Prolia in improving bone density and reducing bone breakdown marke…
Phase 3 • Sponsor: Enzene Biosciences Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New bone drug copycat put to the test in healthy volunteers
Knowledge-focused CompletedThis early-stage trial compared a new biosimilar version of the bone drug denosumab (called ENZ215) with the already-approved brand-name drug Prolia. 207 healthy adult men received a single shot of either the new drug or Prolia. The goal was simply to see if the new version behav…
Phase 1 • Sponsor: Enzene Biosciences Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC